Popular on TelAve
- Althea Gibson Honored as Final Release in U.S. Mint's American Women Quarters Program - 157
- Cyntexa Announces Updates to ChargeOn on Salesforce AppExchange
- 5,000 Australians Call for Clarity: NaturismRE's Petition Reaches Major Milestone
- TradingHabits.com Launches to Support Day Trader Well-being
- BumblebeeSmart Introduces Rounded Busy Board Set for Preschoolers
- Dental Care Solutions Unveils New Website for Enhanced Patient Engagement
- Wohler announces three SRT monitoring enhancements for its iVAM2-MPEG monitor and the addition of front panel PID selection of A/V/subtitle streams
- WHES Retains BloombergNEF Tier 1 Ranking for Sixth Consecutive Quarter
- Vertical Consultants and Cell Tower AI™ Clarify Brand Identity and Digital Presence
- Huntington Learning Center of Russellville Marks 1 Year Anniversary; Extends Reduced Grant-Aligned Rates to All Students in Learning Center Services
Similar on TelAve
- Anderson Periodontal Wellness Attends 5th Joint Congress for Ceramic Implantology
- Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
- Melospeech Inc. Accepts Nomination for HealthTech Startup of the Year
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
- Broadway Smile Boutique Unveils Modern Website for Enhanced Patient Experience
- Signature Smiles Dental Group Unveils New User-Friendly Website
- CCHR: New Data Shows Millions of U.S. Children Caught in Escalating Psychiatric Polypharmacy
- Smile! Dental Center Named 2025 "Best Dentist" in North Pittsburgh, Celebrating High-Tech Care and Heartfelt Service
purelyIV Launches Niagen® IV Therapy – A Breakthrough in NAD+ Cellular Wellness
TelAve News/10870991
Metro Detroit's leading mobile IV therapy provider introduces pharmaceutical-grade Niagen® infusions, offering a faster, more efficient, and more comfortable way to boost NAD+ levels at home.
ROCHESTER HILLS, Mich. - TelAve -- purelyIV, Metro Detroit's leading mobile IV therapy provider, is proud to announce the launch of Niagen® IV Therapy, a groundbreaking new service designed to efficiently boost NAD+ levels. This innovative treatment uses pharmaceutical-grade nicotinamide riboside chloride (NR) to deliver a faster, more comfortable NAD+ replenishment experience compared to traditional NAD+ IV infusions.
Niagen® IV Therapy offers clients a cutting-edge approach to cellular health and wellness. Clinical studies show that Niagen® infusions raise whole-blood NAD+ levels 20% higher than standard NAD+ IV treatments and achieve peak levels within just three hours—while requiring 75% less infusion time. Treatments are typically completed in 30–45 minutes, allowing for a more convenient experience with fewer side effects.
More on TelAve News
"Niagen® IV Therapy represents the next evolution of NAD+ boosting wellness," said Erin Boumansour, co-founder and lead practitioner at purelyIV. "We are excited to bring this advanced therapy to Metro Detroit, offering our clients an efficient and scientifically supported option to enhance energy, support cognitive health, and promote healthy aging—all delivered in the comfort of their home or office."
purelyIV's licensed nurses administer Niagen® IV infusions in 500mg and 1000mg doses with 500ml of fluids and electrolytes. Clients can also choose add-on options like Niagen® IV Push and Niagen® Shots for a quick, convenient boost during other IV treatments.
With its mobile, in-home service model and commitment to clinical excellence, purelyIV continues to lead the way in providing premium IV therapy solutions designed to meet the unique wellness goals of each client.
To learn more about Niagen® IV Therapy or to schedule an appointment, visit https://purelyiv.com/niagen-iv-therapy.
Niagen® IV Therapy offers clients a cutting-edge approach to cellular health and wellness. Clinical studies show that Niagen® infusions raise whole-blood NAD+ levels 20% higher than standard NAD+ IV treatments and achieve peak levels within just three hours—while requiring 75% less infusion time. Treatments are typically completed in 30–45 minutes, allowing for a more convenient experience with fewer side effects.
More on TelAve News
- Inkdnylon Expands National Uniform Embroidery Services
- Appliance EMT Expands Appliance Repair Services to Portland, OR and Vancouver, WA
- Next Week: The World's Best Young Pianists Arrive in Music City for the 2025 Nashville International Chopin Piano Competition
- Revenue Optics Builds Out Its Dedicated Sales Recruiting Firm with Strategic Addition of Christine Schafer
- Hydrofast Elevates the Holiday Season: The C100 Countertop RO System Merges Smart Tech with Wellness for the Perfect Christmas Gift
"Niagen® IV Therapy represents the next evolution of NAD+ boosting wellness," said Erin Boumansour, co-founder and lead practitioner at purelyIV. "We are excited to bring this advanced therapy to Metro Detroit, offering our clients an efficient and scientifically supported option to enhance energy, support cognitive health, and promote healthy aging—all delivered in the comfort of their home or office."
purelyIV's licensed nurses administer Niagen® IV infusions in 500mg and 1000mg doses with 500ml of fluids and electrolytes. Clients can also choose add-on options like Niagen® IV Push and Niagen® Shots for a quick, convenient boost during other IV treatments.
With its mobile, in-home service model and commitment to clinical excellence, purelyIV continues to lead the way in providing premium IV therapy solutions designed to meet the unique wellness goals of each client.
To learn more about Niagen® IV Therapy or to schedule an appointment, visit https://purelyiv.com/niagen-iv-therapy.
Source: purelyIV
0 Comments
Latest on TelAve News
- Verb™ Presents Features Vanguard Personalized Indexing: Utilizing Advanced Tax-Loss Harvesting Technology
- UK Financial Ltd Announces A Special Board Meeting Today At 4PM: Orders MCAT Lock on CATEX, Adopts ERC-3643 Standard, & Cancels $0.20 MCOIN for $1
- 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree
- From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
- Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
- Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
- Canterbury Hotel Group Announces the Opening of the TownePlace Suites by Marriott Portland Airport
- Heritage at South Brunswick's Resort-Style Amenities for Any Age and Every Lifestyle
- T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
- Record Revenues, Debt-Free Momentum & Shareholder Dividend Ignite Investor Attention Ahead of 2026–2027 Growth Targets: IQSTEL (N A S D A Q: IQST)
- New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life
- BRAG Hosts Holiday Benefit — Awards 10 Student Scholarships & Honors Timberland with the Corporate Impact Award
- FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory
- Local Fiber Announces Graduation from Samsung Next Startup Program, Marks New Phase of Growth
- Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
- "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
- Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
